Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Implant in Overweight and Obese Participants
NCT07430059Phase 1Not yet recruiting
- Sponsor
- Vivani Medical
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 1, randomised, open-label trial of semaglutide in obesity (2 arms), sponsored by Vivani Medical. Primary endpoints: Area under the plasma concentration-time curve at 4 weeks, Maximum plasma concentration at 4 weeks and 2 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07430059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07430059.